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Abstract 
Leishmanias is a group of diseases with different clinical manifestations and is 
the leading cause of high morbidity and mortality worldwide. The clinical 
manifestations of Leishmanias in humans depend on complex interactions between 
the virulence characteristics of infecting Leishmania spp. and the immune 
responses of its hosts. The disease can manifest in a number of forms, ranging from 
simple cutaneous ulcers to the involvement of visceral organs, causing highly fatal 
visceral disease or kala-azar. Drug resistance is a very evident problem in some of 
endemic countries within the increasing demand for effective alternatives. The 
urgent demand for a vaccine capable of halting the spread of the disease has been 
exhausting. One of the most important aspects of Leishmania spp. infection is the 
ability of these parasites to evade and sabotage the host immune responses, which 
allow the parasite to persist and established chronic infection. The aim of the 
present dissertation is to investigate Leishmania spp. (L. shawi, L. amazonensis, L. 
guyanensis, and L. infantum) ability in modulating MØ activation, by accessing cell 
phenotype through the expression of two surface biomarkers, CD68 and CD163that 
are associated with phagocytosis and oxidative burst. Results showed that 
Leishmania promastigotes induced a change in MØ phenotype that point towards 
active phagocytosis and inhibition of the oxidative burst. Modulating the MØ 
activity to increase phagocytosis and decrease oxidative burst allows the parasite to 
establish host infection and ensures their own survival and the accomplishment of 
the life cycle, at least by the parasites that cause cutaneous leishmaniasis.  
 
Keywords: Macrophage phenotype; Leishmania spp., Surface biomarkers; 
Phagocytosis; Oxidative burst. 
 
 
 
 
 
  
Resumo 
 
Leishmanioses é um grupo de doenças causadas por parasitas do género 
Leishmania que apresenta elevada morbidade e de mortalidade. As manifestações 
clínicas dependem de interações complexas que se estabelecem entre Leishmania spp. e 
a resposta imunitária do hospedeiro. A doença pode manifestrar-se de maneiras 
diferentes, desde uma simples úlcera cutânea até ao envolvimento dos órgãos profundos 
que pode originar doença visceral fatal ou kala-azar. A resistência a drogas terapêuticas 
é um problema muito evidente em países endémicos, existindo uma crescente procura 
por alternativas eficazes. A pesquisa de vacina(s) capaz de deter a propagação da 
doença tem sido exaustiva. Um dos aspectos mais importante de Leishmania spp. é a 
capacidade destes parasitas conseguirem, por um lado, evitar e, por outro, alterar a 
resposta imunitária  do hospedeito, que permita a  sobrevivência do parasita e do 
hospedeiro,  originando infeção crónica. O objectivo desta dissertação é investigar a 
capacidade de Leishmania spp. (L.shawi, L.amazonensis, L.guyanensis e L.infantum) 
modular a  activação de MØ humanos, avaliando o fenótipo de MØ infetados através da 
expressão de dois biomarcadores de superfície, o CD68 e o CD163, associados à 
fagocitose e á actividade  oxidativa. Os resultados mostraram que promastigotas de 
Leishmania induziram a mudança no fenótipo dos MØ que aponta para a existência de 
fagocitose intensa e inibação da actividade oxidativa. O incremento da fagocitose 
associado á diminuição da actividade oxidativa dos MØ infetados facilita o 
estabelecimento da infeção no hospedeito humano, garante a  sobrevivência do parasita 
e  assegura a conclusão do   seu ciclo de vida, sobretudo nos parasitas causadores de 
leishmaniose cutânea 
 
Palavras-chave: Fenótipo de macrófagos; Leishmania spp., Biomarcadores de 
superfície; Fagocitose, Actividade oxidativa  
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1 - Introduction 
1.1.1 - Leishmania: zoonotic and anthroponotic disease 
Leishmania is an intracellular parasite member of Trypanosomatidae family and 
it is the etiological agent of leishmaniasis, a worldwide endemic disease of tropical and 
subtropical areas, including the Mediterranean region. This disease is considered by 
WHO as one of the most dangerous diseases. Regarding the prevalence and geographic 
distribution and counting at present with about 98 scountries from different continents 
with reported cases (González et al., 2015). Leishmaniasis is a neglected and poorly 
reported disease with an underestimated burden in most countries. Despite of being 
known as a dog disease, and others silvatic and domestic animals be infected by 
Leishmania, such as rodents (Akhounndi et al., 2016), there is a higher rate of human 
infection and in this case leishmaniasis behaves as zoonosis. In other cases the 
transmission is anthroponotic, the infection can be accidental and the parasitic cycle is 
completed in the human body instead in the animal body, and it is more common in the 
Indian subcontinent and during the epidemic spread in East Africa. Leishmaniasis is a 
major health problem that is affecting more than 300 million people (Gurung et al., 
2015), and can be fatal when is not treated appropriately. Overall the incidence is 
underestimated because in the majority of countries are not reported. In some parts of 
both the Old and the New World the transmission can be domestic (Vries et al., 2015).   
Leishmania is a heterogeneous parasite that has the ability of infecting two 
different hosts, vertebrate and invertebrate. The parasite natural habitat is the 
intracellular microenvironment of mammal’s reticuloendothelial system, including liver, 
spleen, bone marrow, lymphatic nodes and the intestinal tract of the insect vector 
(Palatnik-de-Sousa et al., 2011; Akhounndi et al., 2016). 
 The main vector responsible for parasite transmission is the blood sucking 
female of the flebotomine sand fly. There are about of 800 sand fly species described 
and characterized in the New and Old World (Akhounndi et al., 2016). In the New 
World the predominant vector is of Lutzomyia genus and in the Old World is the 
Phlebotomus, and due to their small size and physical appearance, they are sometimes 
mistakenly for mosquitoes (Branco et al., 2010). The female sandflies usually bite when 
night falls and they have differences according to the species (González et al., 2015). 
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The dog is the main domestic and a peridomestic reservoir of L. infantum in 
countries of Southern Europe, the Middle East, Asia, North Africa, Central and South 
America. It is considered a good reservoir because in addition to cohabiting with human 
beings, it maintains the infection for a long time before developing chronic disease, 
allowing several parasite transmission cycles. Despite canine leishmaniasis be 
characterized by a viscera cutaneous involvement, the presence of parasites in the skin 
will facilitates it’s transmission to the vector (Guimarães e Silva, et al., 2017). 
Depending on the parasite species, leishmaniasis can cause different clinical 
forms such has cutaneous leishmaniasis, visceral leishmaniasis, mucocutaeous 
leishmaniasis and kala-azar form. However, several factors influence resistance or 
susceptibility to infection and disease, including genetic variation of the host, genetic 
variation of the parasites between species and strains, age of the host, nutrition, efficacy 
of the immuneresponse and other factors such as the inoculum size and number of 
infective bites received by the host.  
Although the most documented form of transmission is the one that is 
transmitted by the vector, there are other forms of transmission like blood transfusion. 
Congenitally it is another way of transmission, but more rare than the others.  
The disease is characterized by epidemiological and profiles of the several 
species of Leishmania, capable of expressing different clinical manifestations, 
transmitted to several vectors and be kept in mammalian reservoirs. Despite the high 
number of infected human cases, new strategies are needed for a more effective 
intervention for better prevention of leishmaniasis spread, not only in endemic but also 
in non-endemic areas (Guimarães e Silva, et al., 2017). 
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1.1.2 - Taxonomic position  
Around 53 species of Leishmania were described and approximately 20 of them 
infect human beings (Akhounndi et al., 2016). Leishmania was classified in several 
stages with years of difference and by different biologists and is currently classified in 
the Protist Kingdom (by Haeckel, 1866), Class Kinetoplastea (by Honigberg, 1963 
emend. Vickerman,1976), Subclass Metakinetoplastina (by Vickerman, 2004), Order 
Trypanosomatida (by Kent, 1880), Family Trypanosomatidae (by Döflein, 1901), 
Subfamily Leishmaniinae (Maslov and Lukeš, 2012) and Genus Leishmania (by Ross, 
1903). Leishmania is a heterogeneous parasite and has the ability to survive within 
mammalian macrophages (MØ) and in the gut of sandflies (Akhoundi et al., 2016). The 
genus Leishmania is divided into two subgenera depending on its development in the 
vector: subgenus Leishmania with a development in the stomach (suprapylaric); Vianna 
subgenus with an initial development in the hindgut and migration to the vector 
proboscis (peripylaric) (Saridomichelakis, 2009; Akhoundi et al., 2016).  
The first attempts of Leishmania classification were based only on extrinsic 
characteristics, such as geographic distribution, clinical manifestations and development 
in the intestine of sand fly, but the official classification appeared in the early twentieth 
century by Nicolle, who separated L.infantum from L.donovani, which has hampered 
Leishmania taxonomy (Fraga et al., 2010). In the late 1970s, Vickerman proposed, 
dividing into four complexes of species: the donovani complex, the tropic complex, the 
Mexican complex and the Braziliensis complex (Fraga et al., 2010). 
Later, Leishmania parasites were separeated by sections according to the 
intravectorial development: the first one in peripylaria (hindgut and pylorus); and the 
second in suprapylaria (pre pylorus) (Fraga et al., 2010). This division into sections 
allowed Lainson and Shaw to differentiate Leishmania into two subgenera: Viannia to 
periplyaria and Leishmania to suprapylaria (Fraga et al., 2010). 
More recently, using new techniques of differentiation and comparison with the data 
obtained previously, the parasite is classified into two phylogenetic lines: Euleishmania 
that included the subgenus Leismania, Viannia, Sauroleishmania and L. enrietti; and in 
Paraleishmania that includes L.hertigi, L. deanei, L. herreni, L. equatorensis, L. 
colombiensis and the genus Endrotrypanum (Fraga et al., 2010). 
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1.1.3 - Epidimiology and Global Dispersion  
According by WHO, there were reported in 2014 more than 90% of new cases in 
countries like Brazil, Somalia and Sudan. But this statistic varies according to the 
leishmaniasis clinical form, for example the kala-azar form has been less reported, due 
to the elimination program implemented.  
The cutaneous leishmaniasis (CL) of the Old World found in North Africa, 
Median Mediterranean, Northeast of India and Central Asia is frequently caused by L. 
(L) major, L. (L) tropica and L. (L) aethiopica. The clinical features vary between and 
within regions, reflecting different species, immunological status and responses of the 
patients. More recently, in 2017, 94% of new cases were reported in the same countries, 
and there were also an increase of CL in cases in Afghanistan and Syria. As already 
have been said the lack of notification strongly influences the final numbers. At present, 
Turkey, in Europe, is the most affected country by CL, and Turkmenistan and 
Uzbekistan, in Asia, account for almost 80% of total cases reported. Anthroponotic CL, 
which is caused by L. tropica, can be found in Azerbaijan, Israel, Turkey and 
Uzbekistan. The disease is predominantly reported in densely populated communities, 
where person-to-person transmission is maintained by P. sergenti. Cases of zoonotic CL 
due to L. major are mainly registered in South Caucasus and Kazakhstan in central 
Asia, in Israel at Middle East and in Turkey in Europe. Furthermore, L. major infection 
is prone to epidemics (Akhoundi, 2016). 
In the New World (American continent) CL is caused by parasites belonging to 
the L. mexicana complex or to Viannia subgenus. The number of new cases of CL 
(ACL) reported comes from countries such as Colombia and Peru. This is a very 
complex disease, which can be caused by several different species of Leishmania, that 
have diverse reservoir hosts and vectors, and can give origin to different symptons 
(Akhoundi, 2016).  
 Visceral leishmaniasis  (VL) is caused by L. donovani and is mainly found in 
the Indian subcontinent and East Africa and by L. infantum in the Middle East, 
Mediterranean bay and Central and South America (González et al., 2015), and more 
recently were discovered in Australia (Akhounndi et al., 2016). VL may be endemic, 
sporadic or epidemic, with different clinical features in each situation. In areas endemic 
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for VL the disease tends to be relatively chronic, and children are the most affected. In 
the Old World the main species are L.(L) donovani, L. infantum and in the New World 
L.(L) infantum, L. Mexicana and L. (V) braziliensis. 
The number of reported cases has been increasing, especially in non endemic 
areas, due to a long term immigration and tourism in risk areas of contracting the 
parasite (Silva-Almeida et al., 2012). VL cases of due to L. infantum, are reported in 
countries of Western Europe, the Balkan region, central Asia, South Caucasus and 
Turkey, with an overwhelming majority (nearly 75%) found in Albania, Georgia, and a 
minimum percentage in Italy and Spain. The mainly reservoir hosts are domestic dogs, 
but foxes also can be sylvatic reservoirs. The main suspected vectors are thought to be 
P. chinensis, P. ariasi and P. pernicious (Akhoundi, 2016).  
Despite its wide global distribution, leishmaniasis epidemiology depends on: the 
intrinsic characteristics of the parasite species, the local ecological factors, the current 
and past exposure of the human population to the parasite and the human behavior. 
Immunocompetence and lack of nutrition are others factors that will increase the risk of 
VL and mucocutaneous leishmaniasis (MCL). This clinical manifestation causes lesions 
in the mucous membranes, leading to disfigurations, and is most frequently caused by 
Leishmania parasites of the subgenus Viannia, mainly by L. braziliensis (Scorza et al., 
2017). 
The lack of iron, vitamin A and zinc seems to make people more sensitive to the 
spread of disease when in contact with the parasite. Although recent studies suggested 
that the increasing of zinc and iron in nutrition do not cause prevent parasite 
visceralization (Akhoundi, 2016). Other factors that influence the affected population 
are the age and the level of exposure. In endemic foci where the causative parasite is L. 
infantum, patients mean age tends to be under 5 years and in endemic foci of L. 
donovani predominates ages between 13–23 years (Scorza et al., 2017).  
Because the CL clinical manifestations are very similar and generalized, the 
identity of the infecting species should be known as soon as possible. Although in 
Europe the risk of contracting leishmaniasis in humans is low, and when it happens only 
focuses on two groups: immune suppressed by medication and refugees from endemic 
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countries (anthroponotic). In dogs, however, remains highly due to the growing number 
of abandoned dogs or because the owners/tutors do not apply the available anti-
Leishmania protection measures to their dogs.  
About 1 to 2 million people are infected for the first time each year, with 
cutaneous Leishmania, being the most reported the emerging case of public health in the 
Middle East, such as in Syria, where a high incidence has been reported, and although 
there are national programs, vector control and treatment programs implemented for 
infected patients, their spread is worrying, especially in recent years with the increase in 
mass migration (Hijjawi et al., 2016). 
The development of new molecular technologies for detection and identification 
has been an important allied in epidemiological research and management of clinical 
cases, particularly during outbreaks (for example for species determination).  
1.1.4 - Parasite Morphology and Life Cycle 
The parasite has two different morphological phases in its life cycle: the 
promastigote and the amastigote forms. Promastigote parasites are characterized by the 
presence of a flagellum and live inside the gut of their sand fly vector, and amastigote 
parasites, which do not have an external flagellum, can be found inside MØ and 
represents the mammal infective stage.  
During the sand fly blood meal, metacyclic promastigotes, the parasite infective 
form, is inoculated in the host skin. The promastigote forms are deposited on the skin 
and at the dermo-epidermal junction they bind to some molecules in order to 
camouflage their entry into the body, as is the case of collagen (Fatoux-Ardore et al., 
2014). Once metacyclic promastigotes come into contact with a new microenvironment 
have to face different obstacles, such has a high temperature and the innate defense 
mechanisms of the mammal immune system, which includes phagocytes and soluble 
serum factors, such as components of the complement system.  
After phagocytosis, promastigotes differentiate into amastigotes and multiply by 
longitudinal binary fission inside MØ phagolysosome. Due to amastigotes saturation, 
MØ end up undergoing cell lysis, releasing the parasites in the extracellular space where 
found other MØ, being internalized again (Fig.1). By repeating the same cycle 
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facilitates parasite propagation in the organism. When the female sand fly gets another 
blood meal from a parasitized host the ingested amastigotes become procyclic 
promastigotes and multiply by mitosis in the sand fly gut (Solano-Gallego et al., 2011; 
Silva-Almeida et al., 2012) 
As already mentioned, Leishmania presents a dymorphic life cycle, characterized by 
two morphological forms. These forms have a nucleus, a large mitochondria and a 
kinetoplast corresponding to mitochondrial deoxyribonucleic acid (DNA) highly 
condensed in a single region near the basal body. 
 At the local of sand fly bite it is evident an erythema, pointing out the local 
where the parasite was deposited. When the time goes by it can evolve to a CL 
characteristic wound. Within a two week to six month window, the infection 
progression trend is different according to the infecting parasite species. In VL case 
infected MØ home to organs rich in phagocyte cells (such as the spleen) whereas in CL 
become limited to the site of inoculation or are disseminated through the lymphatic 
system to other sites of the dermis, such as cartilage or mucosa (Solano-Gallego et al., 
2011; Silva-Almeida et al., 2012). 
 
 
 
 
 
 
 
 
 
Fig 1.: Representative scheme of Leishmania spp. life cycle. The letter A corresponds to the phlebotomine stage 
and the letter B in the vertebrate stage. 1.  metacyclic promastigotes are introduced into the dermis, in this case the 
human being by female sand flies during their meal; 2. promastigotes are phagocytosed by neutrophils, which are the 
first cells to be activated in the event of an invasion; 3. Parasites differentiated into anastigotes; 4. amastigotes 
replicate within the phagocytosoe of the MØ, causin cell rupture and are again phagocytosed by other MØ; 5. Female 
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sand flies ingest MØ infected with amastigotes; 6. During blood digestion amastigotes are released in the 
extracellular environment; 7. in the sand fly gut the amastigotes differentiate promastigotes; 8. promastigotes 
replicate by mitosis and migrate to proboscis, being able to infect another mammalian host during the next sand fly 
meal  (adapted from CDC, 2018, https://www.cdc.gov/parasites/leishmaniasis/biology.html)  
 1.1.5 - Clinical presentation – Leishmaniasis, the disease  
As already mentioned, 21 species of Leishmania are pathogenic to humans. 
According to their characteristics, signs, symptoms, endemic area, age and nutritional 
state of the host, the immunological status and the efficiency of the immune response 
are classified as Cutaneous Leishmaniasis (CL), Anergic Diffuse Cutaneous 
Leishmaniasis (ADCL), Mucocutaneous Leishmaniasis (MCL), and Zoonotic Visceral 
Leishmaniasis (ZVL) and Anthropoietic (AVL) Visceral Leishmaniasis (Akhounndi et 
al., 2016; Scorza et al., 2017). 
In the Old World the genus Phlebotomus is involved in the transmission of 
different species of Leishmania, and in the New World only the vector Lutzomyia is 
responsible for the transmission of Leishmania (Fig.2). As already mentioned above, the 
development of the parasite in the vector is divided into suprapylaric and peripylaric. 
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Fig.2.: Table of species of Leishmania of Old and New World, geographic distributon, the respective vectores 
and the clinical presentation 
In the Old World, CL begins as a papule at the site of inoculation that over time 
develops a crust, leading to a scar with altered pigmentation. When left untreated, the 
disease is destructive and disfiguring. The low number of amastigotes in the lesion may 
lead to late or incorrect diagnosis. In the Old World is caused by L. major, L. tropica 
and L. aethiopica and in the New World is caused by L. mexicana, L. amazonensis, L. 
venezuelensis, L. braziliensis, L. guyanensis, L. panamensis, L. lainsoni, L. naiffi, L.(V) 
shawi and L. peruviana. (Palatnik-de-Sousa et al., 2011; Scorza et al.,2017). 
 MCL is characterized by the presence of lesions in the nasal and buccal mucosa 
and respiratory tract and is mainly caused by L. braziliensis and L. panamensis .This 
disease is rarely seem in Old World, and is more present in aging people (or people with 
immune suppression). Laryngeal lesions may become chronic and may be mistaken for 
cancer (Palatnik-de-Sousa et al., 2011; Scorza et al., 2017). 
 ACDL is a serious clinical form of CL, presenting multiple, disseminated and 
nodular lesions. It can be a chronic and systemic infection with a fatal outcome if left 
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untreated. It is caused by L. amazonensis and L. aethiopica (Palatnik-de-Sousa et al., 
2011; Scorza et al., 2017). 
 ACDL is a serious cinical form of CL, presenting multiple, disseminated and 
nodular lesions. It can be a chronic and systemic infection with a fatal outcome if left 
untreated. It is caused L. amazonensis and  L. aethiopica (Scorza et al., 2017). 
 ACDL clinical forms, which presents lesions all around the body and commonly 
involves mucosal membranes, can be cause by L. guyanensis and L. amazonensis in the 
New World and by L. aethiopica in the Old World (Scorza et al., 2017). 
 CL recurrences are rare, but may occur after primary infections by species, such 
as L. major or L. braziliensis, This rare form is expressed for varying periods of time. 
The lesions appear around the scars caused by previous lesion, do not cause pain and do 
not form ulcers, unlike the other forms of the disease (Scorza et al., 2017). 
 ZVL is caused by L.infantum and its mains reservoir is the dog, with other 
animals such as foxes, such as sylvatic reservoirs. It is most common in rural areas with 
a varied geographic dispersion (Mediterranean basin, Middle East, Nortwest China and 
Africa). AVL is caused by L. donovani and found more in the Middle East and India 
(Scorza et. al., 2017). About 95% of cases VL occur in six countries: Bangladesh, 
Brazil, Ethiopia, India, South Sudan and Sudan (WHO, 2014). This clinical form affects 
the lymph nodes, spleen, liver and bone marrow. Symptoms are predicted by persistent 
fever, weight loss, hepatosplenomegaly, anemia and lymphdenopathy. Being 
progressive can be fatal.  
Pos-Kalazar Dermal Leishmaniasis (PKDL), is the most severe form of the 
disease, and is a complication of VL. It is characterized by a macular, maculopapular 
and nodular eruption around the buccal mucosa, and can spread throughout the rest of 
the body. It occurs more frequently in Sudan and India, and its caused by L. donovani 
(Scorza et. al., 2017).  
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1.1.6 - L. (L) amazonensis 
L. amazonensis is reported has highly virulent. In Latin America, L. amazonensis 
causes several clinical manifestations such as cutaneous, diffuse cutaneous 
leishmaniasis (although rare and long-lasting, it is caused by an anergic immune 
response, presenting progressive primary lesions and multiple metastatic lesions), and 
mucocutaneous. Is unique among other species because promotes chronic infection due 
to activation of extracellular signal regulated kinases (ERK), having the ability to 
manipulate the host immune response (Tschoeke et al., 2013; Pratti et al., 2016; 
Martinez et al., 2015).  
1.1.7 - L.(L.)  infantum 
L. infantum is the etiological agent of VL, in humans and dogs of the Old and New 
World. The species was described in 1908, by Nicolle in the Old and, by Chagas and 
Cunha in 1937 in South America where it was identified as L. chagasi. Later on, 
molecular researches proved that  L. infantum and L. chagasi  are the same species. 
There are a few cases reported of CL in the Mediterranean basin caused by this species 
(Gouzelou et. al., 2013). In CL, the lesions may be single or multiple of chronic 
evolution. In Portugal  the first CL case caused by  L. infantum zimoderme MON-1 has 
been reportedin 2005 (Campino et. al., 2005). 
1.1.8 -  L.  (V) shawi 
Belonging to the subgenus Viannia, L. shawi has some epidemiologic relevance in 
the New World. Although not greatly studied, recent data were able to demonstrated 
that L. shawi antigens are immunogenic and have beneficial abilities (Jennings et al., 
2014). However, this species causes large mucosal lesions with a severe inflammatory 
process that can progress to necrosis of the affected areas (Jennings et al., 2014). 
Passero and collaborators stated that resistance to L. shawi infection can occur 
through the activation of CD4 + and CD8 + T lymphocytes, and the antigens capable of 
inducing this immunological profile may be good candidates for the development of 
vaccines against ACL (Passero et al., 2012). Despite being a monophyletic species, 
have antigens homologous to other species of Leishmania, which is a positive aspect for 
the development of an effective vaccine able to protect for Leishmania cross infections 
(Passero et al., 2012; Jennings et al., 2014) 
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1.1.9 - L. (V) guyanensis 
 L. guyanensis first described in 1954 occurs in South America and is responsible 
for ACL (Freitas, et. al., 2015; Coughlan et. al., 2018). More and more cases have been 
reported by this species, even in extensive areas separated by hydraulic barriers 
(Scarpassa, et al., 2012). 
2 – Immune System: defense mechanisms 
 After infection, there are factors related to the immune system of the host, as 
well as to the parasite species that influence parasite spread, persistence and latency and 
even infection reactivation (Fernandes et al., 2016). The constant warfare of the host 
immune system against the parasite determines the infection outcome, and subsequently 
the disease evolution (Gupta et al., 2013).  
The Immune System (IS) is composed of tissues, cells and molecules that interact to 
protect the organism against pathogens and structural alterations. The IS functionality is 
based on two types of defense: innate and adaptive immunity. Innate immunity 
represents the first line of defense consisting of anatomical barriers (skin and tissues), 
cells with phagocytic power (such as monocytes), Natural Killer (NK) cells, 
inflammatory mediators and complement system. The adaptive immunity generates 
specific defense strategies for each infectious agent, capable of selectively recognizing 
and eliminating various microorganisms and at the same time memorizing the previous 
contact with pathogens. It consists of B and T lymphocytes, antibodies and soluble 
mediators. 
The constituents of innate and adaptive immunity are recruited to the sites when 
injury or infection occurs to eliminate the pathogens and to resolve the injury. This 
process however, may be beneficial for some situations, but can also give origin to not 
so beneficial responses, like high and lasting fever, hepatosplenomegaly, hemorrhages 
and icterus.  
Leishmania parasites have mechanisms to subvert both innate and adaptive 
immunity (Isnard et al., 2012), escaping to IS deleterious effects and assuring its own 
survival and completion of its life cycle. 
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2.1.1 - Innate Immunity 
The first cells to reach the site of infection are neutrophils, which in turn, destroy 
pathogens and leave the site “quickly” (they enter into apoptosis), while MØ remain in 
the same place for a longer period of time. As soon as the promastigotes are deposited 
in the host's dermis, immediate activation of the complement system occurs. The 
complement factors C3a and C5a are chemotactic, attracting neutrophils and MØ to the 
infection site. However, the parasite is able to inactivate the complement through the 
surface glycoprotein of 63kDa (GP63), which converts C3b into C3i and therefore avoid 
the assembly of membrane attack complex, preventing parasite lysis, contributing to 
parasite phagocytosis by MØ, parasite survival and spread, and infection establishment 
(Gupta et al., 2013). 
2.1.2 - Adaptive Immunity 
When the innate immune response fails to control and / or eradicate the 
infection, adaptive immunity takes effect. Activation is slower, however the response 
generated is specific to the pathogen and produces immune memory, which in the case 
of future infections (by the same pathogen) acts faster and is more effective. It is a 
specific antigen response mediated by lymphocytes, such as B cells (derived from bone 
marrow, involved in the humoral immune response) and T cells (thymus derived, 
cytokine producing cells). T cells regulate the activity of other immune cells, such as the 
BB cells and in particular the anti-parasitic activity of MØ (Gupta et al., 2013). 
B cells only begin to differentiate after exposure to an antigen, while T cells 
require presentation of antigen through antigen presentation cells, as is the case of MØ. 
Although T cells help in eliminating the parasite, they are not able to recognize its 
surface. Thus, these cells have surface receptors able to recognize antigens from 
invading pathogens when complexed with molecules of major histocompatibility 
complex (MHC). Receptors present on the surface of T cells recognize Class I (MHCI) 
and Class II (MHCII) molecules of major histocompability complex. T cells can be 
divided into CD4
+
 (helper Tcells) and CD8
-
 (cytotoxic cells).  CD4
+
 T cells present 
receptors able to recognize antigen-MHCII complexes and the receptors of CD8
-
T cells 
bind to antigen-MHCI complexes. Following antigen recognition process, the selected 
cells differentiate and a clonal proliferation takes place. This process of specific 
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recognition distinguishes self antigens from non-self or invading antigens (Gupta et al., 
2013). 
CD4
+
 cells have several roles in the regulation of immune response. By 
producing anti-innflammatory and pro-inflammatory cytokines, these cells can promote 
MØ functionality, stimulate production of B-cell antibodies, stimulate the cytotoxic 
actibity and controls the intensity and duration of immune response. When CD4
+
 T cells 
lose these functions, the immune response does not have the desired effect and the host 
becomes more susceptible to disorders, such as parasitic invasion. After antigen 
recognition, the selected CD8
+
 cells differentiate and proliferate. These cytotoxic cells 
release granules (that contain perforin and granymes), which promote the lysis of the 
target cell. They are also producers of interferon (IFN)-γ, essential for the control of 
infection by inducing MØ together with tumor necrosis factor (TNF) -  to produce 
nitric oxide (Gupta et al., 2013). 
B cells represent only 15% of total leukocytes and support antibody production. 
Antibodies are immunoglobulins, that in mammals belong to five classes; IgA, IgM, 
IgG, IgE and IgD (Gupta et al., 2013). 
2.1.3 - Monocytes and Macrophages  
Monocytes (Mn) are heterogeneous cells differentiate in bone marrow by the CD34
+
 
cells, a myeloid precursor. One of monocytes main characteristics is the antigen 
presentation, as these cells can express high levels of MHCII. Mn establishes a bridge 
between innate and adaptive immune response, have an active role in homeostasis and 
in the inflammatory process, being crucial in the body’s defense against 
microorganisms invasion. Three days after being in circulation, monocytes penetrate 
different tissues and differentiated into MØ, highly versatile cells, which have an active 
role when facing apoptotic cells and pathogens. Whenever inflammatory processes take 
place, monocytes production increase in the bone marrow and consequently, a hight 
number of these cells rises in the bloodstream. When monocytes progress to MØ, there 
is an increase in phagocytic capacity and the accumulation of hydrolytic enzymes 
(lysosomes). Macrophages are large cells, rich in lysosomes and have a direct 
involvement in host defense. As professional antigen presenting cells (APC), MØ has a 
high affinity with T and B lymphocytes (Raggi et al., 2017).  
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Macrophages, regarded as primary host cells of this parasite, are polarized cells and 
based on the type of stimulation received, they can be activated in two ways: M1 (pro-
inflammatory MØ) or M2 (anti-inflammatory MØ) type. When activated in M1, MØ are 
responding to microbial factors (such as LPS) and to proinflammatory cytokines (such 
as IFN-γ, TNF-α and IL-1β). On the other hand, these cells also can be activated in M2 
by exposure to various stimuli, such as anti-inflammatory interleukins IL-4 or IL-13 
(M2a), by immune complexes combined with IL-1β or LPS (M2b), by regulatory  anti- 
cytokine IL-10 (M2c) or by IL-6 (M2d) (Fernandes et al., 2016; Raggi et al., 2017). 
In M1, the cells show proinflammatory immunostimulatory properties representing 
an important source of reactive oxygen and nitrogen and pro-inflammatory cytokines, 
mediating antimicrobial defense. M2 cells are oriented towards to resolution of any 
inflammation, tissue remodeling, scarring resolution and angiogenesis. MØ still have a 
degree of functional plasticity capable of reversibly changing their activation state, on 
the other hand any polarization disequilibrium may be associated with disorders such as, 
for example, an autoimmune disease or infection in the state chronic (Raggi et al., 
2017). 
Although MØ are at the same time phagocytic cells, they are also, in some ways, 
markers of infection, since they are present for a long period of time. Because they 
remain longer it became an important milestone that would allow us to understand more 
about the parasite-MØ interaction.  
Toll-like receptors (TLRs), expressed by cells that participates in the innate response 
as is the case of MØ, are essential for recognition of the pathogen, its molecular 
patterns, and determinants of infection outcome [(TRL2 recognizes amastigote antigen 
and the promastigote lipophophaglycan ( LPG)]. Another of the TRLs involved is TRL3 
which is activated by the most virulent strains of Leishmania guyanensis and by 
Leishmania of subgenus Vianna, increasing the expression of proinflammatory 
mediators (Gupta et al., 2013). 
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2.1.4 - Leishmania Virulence Factors 
 Leishmania parasite utilizes various surface proteins to enter, to survive inside the 
human organism, to replicate and to disseminate. Glicoinositolphospholipids (GIPL’s), 
lipophosphoglycan (LPG), proteophosphoglycan (PPG), 11 kDa kinetoplastid 
membrane protein (KMP-11) and glycoprotein of 63 kDa (GP63) are indicated as key 
molecules that ensure parasite infectivity (Isnard et al., 2012; Silva-Almeida et al., 
2012). GP63 is described as the major surface antigen expressed in promastigotes of 
various species Leishmania and is synthesized in the endoplasmic reticulum (ER) 
(Isnard et al., 2012).  
Activation of the complement cascade culminates in C3-C3b cleavage. C3b 
opsonizes pathogens, which become being killed by lysis (crucial in innate immunity). 
However Leishmania GP63 as described above, has the ability to cleave C3, converting 
C3b into the inactive form iC3b reducing terminal complement fixation to the parasite, 
thus allowing its resistance to lysis (Isnard et al., 2012). 
2.1.5 - Diagnostic and Treatment 
Over the years diagnostic methods have been improved to fast and accurately 
detect the parasite responsible for causing leishmaniasis. Unfortunately, it is not always 
possible to achieve and obtain a reliable result due to the available infrastructural 
conditions, so sometimes the diagnostic method will have to be adapted. However, there 
is a standard method, as in all diagnoses for the vast areas, which is direct microscopy 
of the parasite (Vries et al., 2015). 
In serology, many methods have already been developed such as indirect fluorescent 
antibody test (IFAT), Enzyme-linked Immunosorbent Assay (ELISA), Western Blot and 
Direct Agglutination Test. However, these methods are not ideal for the detection of 
cutaneous leishmaniasis due to a decrease in the humoral response caused by the 
infection, which results in the low sensitivity of the test. An innovative test (CL 
DetectTM Rapid Test, not currently available on the market) is based on a qualitative 
membrane immunoassay for the detection of all cutaneous Leishmania species (Vries et 
al., 2015). ). The technique of isoenzyme electrophoresis continues to be a very useful 
tool for identifying intrinsic characteristics, like immunological, biochemical and 
molecular markers (Fraga et al., 2010). 
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A variety of rapid tests (quick and easy to perform) are available for VL  
diagnosis, which facilitates the determination of the disease as well as a more effective 
performance, such as IT-LEISH® (DiaMed AG, Switzerland - now Biorad, France), 
Kalazar Detect® (InBios International, USA), Onsite Leishmania Ab Fast Test (CTK 
Biotech, USA). Fluorescence-based serological tests are time consuming, expensive, 
and require more sophisticated laboratory infrastructure (Boelaert et. al., 2014). 
Polymerase chain reaction (PCR) allows amplifying small amounts of parasite 
DNA.  Is a fast technique, of high specificity and sensitivity, allowing detecting the 
presence of Leishmania DNA even in case of asymptomatic individuals. Real-time PCR 
allows assessment of parasite burden and helps to monitor therapeutic responses.  
As already mentioned, depending on the infrastructures there may have to be an 
adaptation of the diagnostic method and in many low-yield laboratories the "detection" 
of CL is based on the patient's clinical history and on the physical examination, without 
recourse to any type of laboratory confirmation test. The risk factors to be taken into 
account are: age, the profession they perform (whether related to outsider activities such 
as agriculture or military activities, among others), whether they live, if lives in rural or 
suburban areas, whether use mosquito nets at home or at work, whether have domestic 
animals. In terms of observable clinical manifestations, ulcerative lesions should be 
taken into consideration for final diagnosis (Vries et al., 2015). 
In most cases, CL eventually leads the infected host to a "self-cure", however, 
the total recovery may go for months to years, and in this period the patient has a very 
weak immune system that results in "exposure" to other potential secondary infections. 
In places where identification of the species its not possible, treatment is based only on 
local therapeutic drug options (Vries et al., 2015).  
There are several drugs for leishmaniasis therapy, but pentavalent antimonials 
remain the first choice in most countries, such as meglumine antimoniate 
(Glucantime®) and sodium stibogluconate (Pentostam®), which allow the blockade of 
glutamic pyruvic transaminase formation (TGP) and adenosine triphosphate (ATP), 
inhibiting phosphofructokinase and pyruvate dehydrogenase, destroying the parasite. 
Despite being the first-line there are already many cases of reported resistance as well as 
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toxicity and side effects. There are other alternative drug therapies such as miltefosine, 
amphotericin B and paromomycin. In addition to etiologic therapy, conjugation with 
symptomatic therapies such as anti-inflammatories, broad-spectrum antibiotic therapy, 
antifungal agents, fluid therapy, blood transfusion, hypoprotein diets and cryotherapy 
may be appropriate (Vries et al., 2015). 
2.1.6 - Prevention 
Although the geographical distribution of leishmaniasis is restricted to certain 
regions of the world, the public health concern caused by the infectious parasite is 
noteworthy. Prevention is always the best weapon of combat. It can be initiated by 
identifying risk groups as well as risk factors, like infected vectors. 
Thus, a way to prevent parasite infection, controlling the increased number of 
reported cases is by reducing vector bites. Sand fly is of small in size, even smaller that 
Anopheles mosquito, the malaria vector. To prevent sand fly bites proper insecticide 
pulverization is a good option. Another way is diminishing the number of infected 
reservoirs, especially in notified areas, therefore reducing parasite transmission. The 
obligation to vaccinate dogs, the reservoir of L. infantum, as a prophylaxis method has 
already proven a reduction in ZVL cases (Vries et al., 2015). 
Prophylaxis vaccination would by far be the best method to combat this disease, 
however, has been a difficult task to get an efficient prophylactic vaccine. 
Individuals infected with Leishmania spp. recovered from infection and become 
resistant to re-infections, being protected, indicating that prophylactic vaccines can be 
developed. Investigations and field research have been increasing in the hope of 
developing the first anti-Leishmania vaccine for more than one species, however the 
current knowledge is still based on animal models that cannot be easily extrapolated to 
humans (Srivastava et al., 2016). 
Deveoping vaccines are divided into: live attenuated Leishmania vaccines; dead 
parasite vaccine consisting of the entire parasite or parasite fractions; vaccine 
constituted of recombinant proteins and DNA vaccines (Srivastava et al., 2016). The 
major difficulty of developing an effective vaccine is realated to the pathogenesis of the 
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parasite ant the host immune responses, since Leishmania has the ability to modulate 
the host immune system. 
Current preventive measures are based on surveillance, development of 
technologies to improve and expedite diagnosis, development of new drug therapies 
(taking into account the resistance already encountered), vector control, and 
consciousness of populations in endemic areas.  
3 - Objectives 
This study investigated the MØ phenotype after being exposed to the following 
Leishmania species: L. guanensis; L. shawi; L. amazonensis and L. infantum. Whenever 
a cell is exposed to a pathogen there is a whole process that begins with the recognition, 
followed by signaling and cell activation, that can cause pathogen elimination. There are 
cases in which the pathogen manages to become "hide" and manipulate the cell in its 
favor, prolonging its lifetime with consequences for the host. Therefore, the present 
study has three main goals: 
3.1.1 – Immunophenotype  macrophage population after being  
exposed to promastigotes of Leishmania spp.  
Using CD68 (a glycoprotein of 110 kDa highly expressed in cells of monocyte/MØ 
linage is related to cell activation and phagocytosis) and CD163 (a glycoprotein of 130 
kDa restrict to monocyte and MØ is associated to the M2 activation) monoclonal  
antibodies as cell-surface-marker, MØ populations exposed to visceral and cutaneous 
Leishmania parasites were evaluated by flow cytometry. 
3.1.2 – Analyze the surface expression level of CD68 and CD163 in 
macrophages exposed to Leishmania spp. promastigotes 
The intensity of CD68 and CD163 in MØ exposed to visceral and cutaneous 
Leishmania parasites were evaluated by flow cytometry. 
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3.1.3 – Assessed macrophage leishmanicide activity 
Metabolization of MØ, arginine and nitric oxide (NO) production, which is a 
powerful leismanicide molecule that mediates killing, was analyzed by Griess reaction. 
4 - Experimental Procedure 
 Blood was collected from healthy volunteers at the Institute of Hygiene and 
Tropical Medicine. After collection with anticoagulant the blood was placed in tubes 
with Histopaque solution. The blood collected along with the Histopaque solution was 
centrifuged, resulting in layering, and the rings were removed and placed in Falcon 
tubes with PBS solution. A wash was done and centrifuged again. The resulting 
supernatant is discarded and the pellet is placed in Falcon tubes and resuspended with 
RPMI with 10% FBS and 20% CFS. The final solution is placed in wells and incubated 
for 72h which is the time that the monocytes reach their maximum differentiation in 
macrophages. At the end of incubation, macrophages are labeled with CD68 and CD163 
and infected with the four Leishmania species: L. guyanensis; L.infantum; L.shawi; 
L.amazonensis. The samples were analyzed by flow cytometry, and at the end compared 
and the results discussed. 
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Fig. 3.: Schematique representation of the experimental design used in the present study. Blood was 
collected from healthy volunteers who were subsequently placed in tubes with Histopaque solution. Total blood was 
layered through centrifugation, and the rings were removed and placed in Falcon tubes with PBS solution and 
washed. The supernatant is discarded and the pellet is placed in Falcon tubes and resuspended with RPMI with 10% 
FBS and 20% CFS. The pellet is plated in wells and incubated for 72 h, which is the time that monocytes reach their 
maximum differentiation in macrophages. At the end of the incubation the macrophages are labeled with CD68 and 
CD163 and infected with the species of Leishmania: L. guyanensis; L.infantum; L.shawi; L.amazonensis. Final 
samples were treated and analyzed by flow cytometry, and MHCI and MHCII results were compared. 
4.1.1 - Sample 
In this study were used samples of fresh human blood, collected from a group of 
healthy people with age between 23 and 35 years. The collections were all done at the 
Instituto de Higiene e de Medicina Tropical and the volunteers were informed about the 
nature of the study and signed an informed consent. 
4.1.2- DAT Protcol 
To confirm that the volunteers have no contact with the parasite, the direct 
agglutination test (DAT) was used to detect antileishmanial antbodies. When become 
positive, this assay shows a light blue plate over the well of the positive sample, and if it 
is negative the sample is deposited in the bottom of the well and forms a stain of dark 
Peripheral Blood Colection from Healthy Volunteers 
Isolation of Mononuclear Cells  
Monocytes  --  Macrophages 
L. infantum 
L. guyanensis 
L.amazonensis 
L. shawi 
CD68 and CD163 
Surface  expression 
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blue color. An incubation is performed using V-bottom microplates. A 50 µl diluent 
solution is used in each well [composed of 0.15 M HCL, 0.2% gelatin (Sigma-Aldrich) 
in distilled water and 0.2 M 2 -mercaptoethanol (Sigma-Aldrich)]. For negative control 
in the wells only the diluent solution was placed and for the positive control serum 
samples of patients with zoonotic visceral leishmaniasis. Then, undiluted serum samples 
of healthy volunteers (50 L) were placed in a 96-well plate, 50 L of L. infantum 
antigen was added, and at the microplates were incubated overnight at room 
temperature.The plates were incubated overnight at room temperature. The results were 
visually evaluated and are expressed as the maximum dilution at which agglutination is 
observed. 
The positive samples were kindly provided by Prof. Carlos Henrique Nery 
Costa, from the Federal University of Piauí (Teresina, Brazil), and the antigen was 
generously given by Prof. Saul Semião Santos, from Tiradentes University (Aracaju, 
Brazil). 
4.1.3 - Isolation of peripheral blood mononuclear cells 
The blood samples were collected into tubes, with the anticoagulant 
citratephosphate dextrose adenine (CPD-1) (Polymed) to prevent clot formation, which, 
if it happens, could make the collected sample unfeasible. 
A volume of 3 mL of Hystopaque® (density 1.077 g.mL
-1
, Sigma-Aldrich), a 
solution of polysucrose and sodium diatrizoate, that is used to create a density gradient, 
were placed in Falcon tubes, and 3 mL of blood was carefully laid on. Tubes were 
centrifuged at 2000g (RCF) at 25 ºC (room temperature) for 20 min. After 
centrifugation, was possible to observe layers (rings) of different densities. These rings 
act as a barrier between the cells of higher density (polimorfonuclear and erythrocytes), 
which is at the bottom of the tube, and the layer which contains mononuclear cells 
(lymphocytes and monocytes). With the help of a Pasteurs pipette, the layer of 
mononuclear cells was carefully removed, avoiding blood dragging and placed in a 50 
mL Falcon tube. Tubes were fulfilled with phosphate saline (PBS) solution and three 
washes were made by centrifugation at 1200g, during 7 min at room temperature. 
Between the washes the supernatant was removed and more PBS solution was added to 
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the total volume of 50 mL was pre-filled, cleaning the cells that will set down at the 
bottom of the tube. 
4.1.4 - Monocyte culture and MØ differentiation 
After washing, the final pellet was resuspended in Roswell Park Memorial 
Institute Medium (RPMI) 1640 (Lonza) at pH 7.2 supplemented with 2 mM L-
glutamine (Merck), 100 μg.mL-1  of streptomycin (Sigma-Aldrich) (complete RPMI 
1640 medium), 10% (v/v) of heat-inactivated fetal bovine serum (FBS) (BioWhittaker) 
and 20% (v/v) of colony stimulating factor (CSF – hybridoma secreted glycoproteins 
that bind to monocyte surface receptors, inducing monocyte proliferation and MØ 
differentiation). Complete RPMI 1640 medium supplemented with 10 % FBS is an 
enriching medium and a source of nutrition for MØ.  
After the washes it is necessary to know the concentration of viable cells, as the 
centrifugation can cause the lysis of some cells, thus increasing the number of non-
viable cells. A trypan blue dye was used to stain the non-viable cells. The concentration 
of viable cells was estimated in a Neubauer counting chamber under optical microscope 
(OM). 
Since one of the objectives of the study was to obtain the largest number of 
monocytes, after washing and determination of viable cells, the next step was to 
maximize the number of MØ. Cell suspension were placed in a six wells plate (3 mL 
per well) and incubated for 72 h at 37 º C ± 1 ºC, in a humidified atmosphere with 5 % 
CO2 until achieved complete differentiation on the 3th day of culture.  
Every 24 h, cell growth was observed to verify if there is any contamination that 
could make the sample non viable for the study and to replace the medium by fresh 
medium heated in a water bath at 37 ºC ± 1 ºC, in order to avoid a thermal shock that 
could alter cell growth and differentiation and to prevent cell malnutrition. 
4.1.5 - Leishmania cultures  
 As it was mentioned before, four species of Leishmania were used in this study. 
The species of L. infantum (MCAN/2012/IHMT0003SG) was isolated from a case of 
canine leishmaniasis from Seixal municipality (Portugal) and maintained in BALB/c 
mice by successive passages. L. amazonensis (MHOM/BR/1973/M2269) was isolated 
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N = n 50  DF  10ᶟ 
from a patient with ACDL, in Pará (Brazil), L. shawi (MHOM/BR/96/M15789) was 
obtained from a patient with CL from Buriticupu (Maranhão, Brazil), and L. guyanensis 
(MHOM/BR/2001/M19663) was isolated from a patient with CL in Santarém 
(Pará,Brazil). The identification of cutaneous species was based on monoclonal 
antibodies and multilocus enzyme electrophoresis at Institute Evandro Chagas (Passero 
et al., 2012). The cutaneous species of Leishmania kindly provided by Dr. F. Passero 
were maintained criopreserved. 
Parasites were cultured in Schneider's Insect Medium (SCHN, Sigma-Aldrich) 
supplemented with 10% FBS (v/v) and penicillin-streptomycin (Biochrom, Germany) at 
100 U.mL
-1
  and 100 μg.mL-1  respectively (complete SCHN medium ), and incubated at 
24 °C ± 1 °C in a refrigerated incubator (Lovibond, Germany). Then, promastigotes 
concentration (promastigotes.mL
-1
) was determined in a Neubauer chamber under 
optical microscope, using a Neubauer chamber and the following equation: 
 
N   - Promastigotes. mL
-1
 
n   - Total number of promastigotes counted  
50 - Factor associated with the number of squares counted  
DF - Dilution factor  
10ᶟ- Volume correction factor  
4.1.6 – Production of Leishmania antigen 
To produce Leishmania soluble antigens of the species to be used for MØ 
stimulation, cultures with a concentration of 1  108 promastigotes.mL-1. Were 
centrifuged at 1800 g for 15 min at room temperature. The pellet was resuspended in 
PBS and again centrifuged at 1800 g for 15 min. Then, the resuspended pellet was 
subjected to six cycles of freezing / thawing (with temperatures varying between 4 and 
24 ° C) to provide cell lysis. Finally, the protein concentration was determined in a 
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Nanodrop 1000 (Spectrophotometer, EUA), and adjusted to 40 mg.mL
-1 
in PBS 
medium. Antigens were stored at -20 °C until further use. 
4.1.7 - Leishmania count 
To have a ratio of 1 MØ for 3 promastigotes it was necessary to estimate the 
promastigote concentration of each Leishmania species involved in the current study. 
Cultured promastigotes (1 mL) of was placed in a tube with a glycerol- RPMI solution 
and a 1:5 dilution was made in an Eppendorf tube. Mobile promastigotes were counted 
in the four4 of the inner square of a Neubaeur chamber (2 upper and 2 lower) and the 
final concentration was estimated, using the following formula. 
1. C [ ] = 
        
 
     cells. mL -1 
C [ ] – concentration 
x, y, z,w = number of promastigotes in the  quadrants of the Neubaeur chamber 
 
4.1.8 – Macrophage infection by Leishmania spp. 
After the end of the incubation time (of the differentiation) of the macrophages, it is 
necessary to make a cell count in Neubaeur's chambers (to evaluate and to count the 
number of viable macrophages to make the infection). At the end the cell concentration 
should be adjusted to. At least three counts should be made at different "plate sites" and 
three fields per "location" using the following formula: 
             
     
 
 
x, y,w - number of cells per field 
After counting the macrophages by fields, calculate the number of cells per well by 
the following formula: 
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Finally multiply the number of cells per well by 3 to obtain the amount of 
Leishmania spp. add to each well. 
After knowing the amount of Leishmanias spp. add the four species per well. Each 
species has a different incubation time: L.infantum and L.amazonensis have 5 h of 
incubation; L.shawi 18 h incubation; L. guyanensis 24 h incubation. At the end of each 
incubation the medium should be removed and a 0.90% cold NaCl solution added (or 
use PBS). Place on a plate with ice for 30 min and centrifuge at 300 ×g for 8 min. 
Discard supernatant and resuspend 100 ul with buffer solution and re-incubate for 30 
min on ice and protected from light. Wash with PBS (at least 1 time) at 300 ° C for 8 
min. At the end of the centrifugation fix with 500 μl of 2% paraformaldehyde and 
incubate again for 20 min on ice and remove from the light. Do one last centrifugation 
at 400 × g (as the cells in the test are losing weight, it is necessary to change the 
rotation) for 10 min. At the end resuspended the pellet in 500 ul in PBS solution and 
store at - 4 ° C until use. In the plates, antigen, anticorpos and the four species of 
Leishmania were placed in each well, along with the positive and negative controls to 
be analyzed by flow cytometry (Fig 4). 
 
 
Fig 4.: Representation of the well plates: Blood monocyte differentiated MØ were infected with L. infantum, L. 
amazonensis, L. shawi and L. guyanensis  promastigotes (L). In parallel unprimed MØ (MØ) was used as negative 
control and MØ stimulated with PMA(MØ+PMA) were used as positive control. Cells were also stimulated with L. 
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infantum, L. amazonensis, L. shawi and L. guyanensis soluble antigen (AG) Cells were marked with human  
monoclonal  antibody anti CD68 and anti CD163. 
.  
4.1.9 - Flow cytometry 
Flow cytometry is a widely used technique for analyzing multiple particle and 
cell characteristics through a liquid medium such as size (which is represented by light 
scattering), internal complexity (represented by the dispersion of the angle), cell cycle 
production and also immunophenotyping by evaluating the expression of surface and 
intracellular markers, using monoclonal antibodies associated with fluorescent 
molecules, called fluorochromes. This technique is based on the measurement of 
fluorescence, as well as its variation, measured between events (Fig.5). It is a technique 
increasingly used in several areas due to its ability to analyze individual cell with high 
sensitivity. 
 
Fig 5: Components of a flow cytometry (https://www.labome.com/method/Flow-Cytometry-A-Survey-and-
the-Basics.html).  
 This method allows distinguishing two (or more) populations in the same 
sample, based on the change in in size and complexity and also fluorescence. As all 
cells emit an autofluorescence it is necessary to separate the living cells from the dead 
(Brown and Wittwer, 2000; Houston et al., 2010). 
The results are presented by graphs charters, such as histograms in which the y-
axis shows the number of events and the x-axis indicates size, complexity or the 
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fluorescence intensity and dot plot which is a graphical representation of two parameters 
in which each point corresponds to a single cell. The scales used in the axes, linear or 
logarithmic, depend on the intensity of the fluorescence of the amount of cells. The 
difference between the linear and the logarithm is that the first is used in cases of low 
intensity variation and the second in cases of greater oscillation of the fluorescence,  
 
A  B 
Fig. 6.: Example of flow cytometry data represented by histogram and dot-plot. The histogram measuring the 
intensity of the FITC signal vs the number of events (A); a scatter plot, used to define the size forward scatter and the 
complexity side scatter of the cells (B). 
Prior to use, a cytometer should be rinsed, cleaning the impurities that may remain. 
 
Fig.7 :. Representation of the plate used in the flow cytometry apparatus. Microplate wells used for initial 
cleaning of the flow cytometer. 
In the current study at first reading, no marked resting-MØs were used. In the 
following readings FITC labeled (fluorescein isothiocyanate) corresponding to CD68, 
and MØ marked with APC, corresponding to CD163, were used. 
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4.2.1 - Nitric Oxide Test 
Nitric oxide has several regulatory functions and can be produced by active MØ 
at high levels. These levels are toxic to infectious agents, but can also be harmful to 
"healthy cells", since overproduction is secreted to the surrounding tissues (Forstermann 
et al., 2011). In general, infected Ø can produce nitric oxide (NO). NO is generated by 
inducible NO synthase (iNOS), an enzyme that catalyzes the oxidation of L-arginine in 
NO and L-citrulline. Supernatants of resting-MØ, PMA-stimulated MØ and MØ 
exposed to Leishmania promastigotes for 5 h were used to quantify total nitrate plus 
nitrite by Nitrate/Nitrite Colorimetric Assay Kit (Abnova, Taiwan). This method 
converts the ion NO3
-
 present in the supernatants to ion NO2
-
 by the enzyme nitrate 
reductase. Subsequent addition of Griess reagent converts NO2
-
 in the azochromophore 
pink/purple compound, allowing the determination of total concentration of both 
metabolites in the sample. The assay was made according to the manufacturer’s 
instructions and without sample dilution. 
The first step was to add 200 l of water to one blank well and add 80 ml of 
samples to others wells. By adding we have to make sure that there is no bubbles enter 
to the wells to avoid erroneous results. After, we add 10 ml of Enzyme Cofactor 
Mixture and more 10 ml of Nitrate Reductase Misture to every well. The plate was 
covered and incubated for 1 h at room temperature. Then, 50 mL of Reagent R1 and 50 
mL of Griess Reagent R2 were added to each well. The plate was incubated for 10 min 
at room temperature. A standard curve was built to estimate the concentration of the 
metabolites in the sample, by reading the absorbance of known NO3 amounts (final 
concentrations between 35 M and 5 M). The absorbance was read at 540 or 550 nm, 
using a plate reader (Anthos 2010, Austria).  
4.3 – Statistical analysis 
Statistical analysis was performed using GraphPad Prism software package version 
8.1.1. Data normality was assessed using the Kolmogorov-Smirnoff test and the 
nonparametric Wilcoxon Signed Ranks Test was used to compare the expression levels 
of CD68 and CD163 surface markers in samples exposed to the four species of 
Leishmania: L. amazonensis; L. shawi; L. guyanensis; L. infantum. Differences were 
considered significant when p < 0.05. The data were work in the FlowJo_V10 program. 
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5 – Results  
  
5.1 –   Blood donors were negative for anti-leishmanial antibodies  
Sera form all participants included in the study tested by DAT presented negative 
results. These results indicate that there is no evidence of previous contact with L. 
infantum. 
5.2 - Cutaneous species and the visceral species of Leishmania were uptake by 
macrophages 
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Fig 8.: Macrophages infected  with Leishmania spp. Macrophages were exposed to promastigotes of L 
.amazonensis (la) and  L. infantum (li) for 5 h, L. shawi (ls)  for 18 h,  and L. guyanensis (lg) for 24 h at  a  
MØ/parasite ratio of 1:5. 
During the infection phase, MØ macrophages were exposed to the 4 Leishmania 
species chosen. The infection phase was 5h and after that only infected macrophages 
were counted. The results obtained were as expected. 
The percentage of infected cells in cutaneous species is higher when compared 
to the visceral species under study, L.infantum (44.77%). Of the cutaneous species, 
L.guyanensis presented the highest infection rate (70.4%), and L.shawi and L. 
amazonensis had similar results (62.16% and 58.53%, respectively). 
5.3. Leishmania spp. promote activation of macrophage phagocytosis  
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Figure 9.: CD68+ macrophage subset after being infected with Leishmania spp.. Macrophages exposed to 
promastigotes of L. shawi (A and E), L. guyanensis (B and F), L. amazonensis (C and G), and L. infantum (D and H) 
were labeled with anti-CD68 monoclonal antibody. Dot-plots representative of each species are shown (E, F, G, and 
H). Results of ten samples and two replicates are expressed by whisker box-plots, median, maximum and minimum. 
*(p<0.05); *** (p<0.001); **** (p<0.0001) indicates statistical differences.  
 
In the readings, made by the cytometer, the graphs show a well-defined population 
where parasite-infected and CD68-tagged macrophages are found, and other 
"population" with no limited marking representing cells that were not tagged and / or 
infected (may also represent cells dead and / or "cell junk" since they also emit 
autofluorescence). MØ population exposed to Leishmania parasites presented a 
predomination of CD68
+
MØs and CD68
- 
MØs  exhibited a low frequency when 
exposed to cutaneous species of Leishmania (p lsCD68* <0.0001, p lsCD68- <0.0001; p 
lgCD68+ <0.0001, p lgCD68- <0.0001; p laCD68+ =0.0002, p laCD68- <0.0001). However, L. 
infantum parasites seem to promote the expansion of CD68
-
MØ (p liCD68+ = 0.0443, p 
liCD68- = 0.0001). Taken together, these results suggest that the presence of parasites that 
cause American cutaneous leishmanaisis lead to activation of macrophage phagocytosis. 
Although L. infantum also induced macrophage phagocytosis, a considerable proportion 
of MØ did not seem to be activated.   
 
5.4. – Leishmania spp. promote the differentiation of M2-macrophages  
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Figure 10.: CD163+ macrophage subset after being infected with Leishmania spp.. Macrophages exposed to 
promastigotes of L. shawi (A and E), L. guyanensis (B and F), L. amazonensis (C and G), and L. infantum (D and H) 
were labeled with anti-CD163 monoclonal antibody. For comparison resting  MØ were also evaluated. Dot-plots 
representative of each species are shown (E, F, G, and H). Results of ten samples and two replicates are expressed by 
wisker box-plots, median, maximum and minimum. *(p<0.05);*** (p<0.001); **** (p<0.0001)  indicates statistical 
differences.  
In the readings, made by the cytometer, the graphs show a well-defined 
population where parasite-infected and CD163-tagged macrophages are found, and 
other "population" with no limited marking representing cells that were not tagged and / 
or infected (may also represent cells dead and / or "cell junk" since they also emit 
fluorescence). MØ population exposed to L. shawi (p ls <0.0001), L. guyanensis (p lg 
=0.001) and L. infantum (p li =0.0384)  parasites presented a significant high expansion  
of CD163
+ 
MØ  subset that showed higher frequencies than resting unmarked MØ (Fig. 
10. A, B and D). L. amazonensis exposed-MØ also presented a higher level of CD163
+ 
MØ although not significantly different of resting MØ (Fig.10. C). Furthermore, 
CD163
- 
MØ evidence low frequencies in all cases. However, this cell subset showed 
minimal values when exposed to the parasites of subgenus Leishmania (Fig.10 C and 
D). Taken together, these results suggest that the presence of parasites stimulate the 
differention of M2-MØ that favor parasite survival and that the expansion of this cell 
subset was considerable when cells were infected with species of subgenus Vianna.   
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5.5. – Leishmania spp. enhance the density  of surface CD68 molecules and  L. 
amazonensis  direct macrophage to highly express CD163 
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Figure 11.: Surface expression of CD68 and CD163 in Leishmania-infected MØ. The fluorescence intensity  of  
CD68 (A and B) and CD163 (C and D) was analyzed in MØ exposed to  L. shawi  (LS), L. amazonensis (LA), L. 
guyanensis (LG) and L. infantum (LI) were evaluated by flow cytometry. In parallel resting MØ and PMA stimulated 
MØ were used as negative and positive control, respectively. Histograms showing fluorescent intensity of resting and 
marked cells (B and  D)  are shown. Results of ten samples and two replicates are expressed by box-plots, median, 
maximum and minimum. *(p<0.05) and ** (p<0.01); indicates statistical differences.  
A B 
C 
D 
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Parasite exposure significantly increases the density CD68 molecules at the MØ surface 
(Fig.11A) when compared with resting MØ (p ls = 0.0059, p lg = 0.0098, p ls = 0.0020, p 
li = 0.0020) and PMA stimulate MØ (p ls = 0.0020, p la = 0.0020, p li = 0.0098).  On the 
other hand, only MØ exposed to L. amazonensis evidence a significant increase of 
surface CD163 molecules (p la =0.0371)  when compared with resting MØ (Fig. 11 B). 
These results indicate that Leishmania parasites induce the host cell to highly express 
the marker of phagocytosis activity, but only L. amazonensis parasite stimulates  cells to 
increase the  expression of molecules associated to the M2 phenotype.    
 
 5.6. – Cutaneous species of Leishmania modulate macrophage oxidative burst 
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Figure 12.: Nitric oxide production by macrophage exposed to Leishmania spp. Supernatants of blood monocyte 
derived macrophages incubated with promastigotes of L. amazonensis (LA), L. infantum (LI), L. shawi (LS) and L. 
guyanensis (LG) at a MØ/parasite ratio of 1:5 for 5 h were used to evaluate NO release. In parallel, supernatants of 
resting MØ and of PMA-stimulated MØ were also assessed. Results of ten samples and two replicates are expressed 
by box-plots, median, maximum and minimum. ** (p<0.01) indicates statistical differences. 
When compared with resting MØ, Leishmania that causes American cutaneous 
leishmaniasis induce MØ to significantly reduce NO production (p ls =0.0020, p ls = 
0.0020, p lg = 0.0020). On the other hand, L. infantum promastigotes do not promote 
significant changes in NO levels (Fig. 12). These results point towards the early 
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negative regulation of MØ oxidative burst by cutaneous Leishmania species, which 
assure parasite survival. 
6 - Discussion  
 Leishmaniasis has one of the highest morbidity and mortality rates of major 
impact in the world. In some endemic areas, the disease is controlled, but in other areas 
of the planet the cases reported increase every year. One of the main problems is the 
control of the various vectors and the increase of resistance of the parasite to the 
antoleishmanial drugs that, until now, remain limited to a few therapies. The 
development of an effective vaccine is still an expectation as well as the discovery of 
alternative drugs.  
 According to Gupta et al., (2014) the best time to achieve a good infection is 
when Leishmania spp. differentiate into metacyclic promastigotes (“zombie mode”, Fig. 
13.), which is at the stage where they are not 100% active, which it is like what happens 
inside the host.  
  
Fig. 13. Graphical representation of the ideal moment of infection by cultured promastigotes of Leishmania 
spp. 
Leismania spp. developed strategies to prevent host immune responses by surviving 
within the host. Macrophages are phagocytic cells, located in lymphoid and non-
lymphoid tissues, and antigen presenting cells, which contribute to the connection 
between innate and acquired immunity. In phagocytosis, Leishmania promastigotes are 
internalized in endosomal compartments, where they become amastigotes. To avoid the 
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hostile environment of phagolysosome, promastigotes transiently prevent fusion of 
phagosomes and lysosomes by retarding or inhibiting endosomal maturation. 
The production of exosomes in Leishmania seems to be the main secretory pathway 
used by the parasite to export its virulence factors inside and outside host cells (Soulat 
et al., 2017). 
 In the present study, the activity of human MØ exposed to species of Leishmania 
that are responsible for American cutaneous leishmaniasis and to L. infantum, the 
species that cause zoonotic visceral leishmaniasis were indirectly evaluated by the 
expression of surface cell biomarkers that are associated with MØ phagocytosis and M2 
phenotype. Unlike apicomplexa parasites Plasmodium and Toxoplasma, Leishmania 
promastigotes are not able to enter in cells by itself, they have to be phagocytosis.  In 
the present study, all species of Leishmania evaluated were able to infect human MØ. 
These findings are in agreement with the expression of the phagocytosis biomarker on 
MØ surface. In fact, most of MØ exposed to cutaneous species of Leishmania exhibited 
CD68
+ 
phenotype. Furthermore, the density CD68 on cell surface also evidence a 
accentuate increase, which is indicative of actively phagocytic MØ. Previous reports by 
Taheri et al., (2017) and Terreros et al (2017) indicate that in CL lesios there is a 
predominance of CD68
+ 
MØ  
 As expected, when exposed to L. infantum promastigotes most of MØ were 
CD68
+
 and also exhibited higher density of CD68 molecule at the cell surface, pointing 
towards active phagocytosis. However, an important part of MØ population was CD68
-
, 
which indicates that not all cells were involved in parasite phagocytosis. Since in this 
case, MØ were exposed to parasites for a short time (5 h) it is possible, that a long time 
to parasite exposure will increase the cells involved in L. infantum phagocytosis. 
Hofman et al, (2000) found CD68
+
 MØ  in cutaneous  inflammatory infiltrates of HIV+ 
patients with viscerocutanous leishmaniasis caused by L. infantum parasites. 
 The cutaneous species of Leishmania promote a decrease in NO synthesis and 
L.infantum does not seem to disturb the arginine metabolic pathway that leads to the 
expression of nitric oxide synthase 2 (NOS2) and to NO synthesis and citrulline release 
by MØ (Bogdan et al., 2000). However, exposure to Leishmania promastigotes causes the 
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expansion of CD163
+ 
MØ, pointing towards the differentiation of  M2 phenotype. M2-MØ can 
metabolize arginine, driving the production of ornithine and urea (Muxel et al., 2017). The 
inhibition or non-activation of M1-MØ favors parasite survival and the increase of M2-MØ can 
have an effect in reducing the severity of Leishmania lesions (Bi et al., 2019). Therefore, 
intracellular Leishmania parasites modulate MØ activity, favoring their own survival and 
prolonged (chronic) host disease (reducing severity), maximizing parasite transmission. 
According to Silva et al.  (2017)  Leishmania infection induced CD163 expression on 
the surface of monocyte/macrophage cells, which can be a potential biomarker of 
disease severity caused by Leishmania spp. 
 
Curiously, L. amazonensis, which presents a predomination of M2-MØ (but not a 
significant expansion of this MØ subset) is the only species that promote a higher 
increase of CD163 molecules at MØ surface. This biomarker is a monocyte-MØ-
specific antigen associated with inflammatory process that usually occurs in acute and 
chronic inflammatory disease (Brune et al., 2013), as is the case of amazonensis-
cutaneous leishmaniasis. 
Thus, the present study demonstrates that despite there are same some minor 
differences between Leishmania spp., both the cutaneous and visceral species were able 
to modulate MØ phenotype, promoting phagocytosis and, at the same time, avoiding 
oxidative burst activation, which are crucial for parasite replication. By regulating MØ 
activity, the parasite ensures its own survival, dispersion and transmission.   
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